High Use of SABAs is Associated with Higher Exacerbation Rate in Dutch Patients with Asthma

References

• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2019. Available from: www.ginasthma.org. Accessed June 23, 2021.
   Google Scholar
• Price D, Fletcher M, van der Molen T. Asthma control and management in 8000 European patients: the REcognise Asthma and Link to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Sawyer SM, Everett PW, Flood PV, Peters MJ. Asthma control in Australia: a cross-sectional web-based survey in a nationally representative population. Med J Aust. 2015;202(9):492–496. doi:10.5694/mja14.01564
   PubMed Web of Science ®Google Scholar
• Sims EJ, Price D, Haughney J, Ryan D, Thomas M. Current control and future risk in asthma management. Allergy Asthma Immunol Res. 2011;3(4):217–225. doi:10.4168/aair.2011.3.4.217
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–938. doi:10.1016/j.rmed.2011.01.005
   PubMed Web of Science ®Google Scholar
• Azzi EA, Kritikos V, Peters MJ, et al. Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists: an Australian community pharmacy-based survey. BMJ Open. 2019;9(8):e028995. doi:10.1136/bmjopen-2019-028995
   PubMed Web of Science ®Google Scholar
• Slejko JF, Ghushchyan VH, Sucher B, et al. Asthma control in the United States, 2008–2010: indicators of poor asthma control. J Allergy Clin Immunol. 2014;133(6):1579–1587. doi:10.1016/j.jaci.2013.10.028
   PubMed Web of Science ®Google Scholar
• Paris J, Peterson EL, Wells K, et al. Relationship between recent short-acting β-agonist use and subsequent asthma exacerbations. Ann Allergy Asthma Immunol. 2008;101(5):482–487. doi:10.1016/S1081-1206(10)60286-4
   PubMed Web of Science ®Google Scholar
• Sears MR. Deleterious effects of inhaled β-agonists: short-acting and long-acting agents differ. Chest. 2001;119(5):1297–1299. doi:10.1378/chest.119.5.1297
   PubMed Web of Science ®Google Scholar
• Anis AH, Lynd LD, Wang XH, et al. Double trouble: impact of inappropriate use of asthma medication on the use of health care resources. CMAJ. 2001;164(5):625–631.
   PubMed Web of Science ®Google Scholar
• Physicians, R.C.o. Why Asthma Still Kills: The National Review of Asthma Deaths (NRAD) Confidential Enquiry Report. London: RCP; 2014. Available from https://www.rcplondon.ac.uk/file/868/download. Accessed September, 2019.
   Google Scholar
• Gibson P, Henry D, Francis L, et al. Association between availability of non-prescription beta 2 agonist inhalers and undertreatment of asthma. BMJ. 1993;306(6891):1514–1518. doi:10.1136/bmj.306.6891.1514
   PubMed Web of Science ®Google Scholar
• The IPCRG. Asthma guidelines used by primary care in Netherlands. Available from https://www.theipcrg.org/display/ResMapping/Netherlands%3A+Asthma. Accessed September 18, 2019.
   Google Scholar
• NHG-Standaard Astma bij volwassenen (Derde herziening) Smeele I, Barnhoorn MJM, Broekhuizen BDL, Chavannes NH, et al. NHG-werkgroep astma bij volwassenen en COPD. NHG-standaard astma bij volwassenen (derde herziening)].
   Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2018. Available from: www.ginasthma.org. Accessed June 23, 2021.
   Google Scholar
• van der Molen T, Fletcher M, Price D. Identifying patient attitudinal clusters associated with asthma control: the European REALISE survey. J Allergy Clin Immunol Pract. 2018;6(3):962–971. doi:10.1016/j.jaip.2017.10.007
   PubMed Web of Science ®Google Scholar
• Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234–1240. doi:10.1016/j.jclinepi.2008.01.006
   PubMed Web of Science ®Google Scholar
• Turner C, Martin E, Eds. Surveying Subjective Phenomena. Vol 2. Russell Sage Foundation; 1984. Available from: www.jstor.org/stable/10.7758/9781610447003. Accessed January 10, 2020.
   Google Scholar
• Yang JF, Chaudhuri R, Thomson NC, et al. Insights into frequent asthma exacerbations from a primary care perspective and the implications of UK National review of asthma deaths recommendations. NPJ Prim Care Respir Med. 2018;28(1):35. doi:10.1038/s41533-018-0103-9
   Web of Science ®Google Scholar
• Radzik D, Peroni DG, Pescollderungg L, Piacentini GL, Chatzimichail A, Boner AL. Nebulizers or pressurized metered-dose inhalers in the treatment of asthma exacerbations. Allergy Asthma Proc. 2005;26(3:207–209.
   Web of Science ®Google Scholar
• Johnston SL, Edwards MR. Mechanisms of adverse effects of β-agonists in asthma. Thorax. 2009;64(9):739–741. doi:10.1136/thx.2009.119230
   Web of Science ®Google Scholar
• Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55(4):1901872. doi:10.1183/13993003.01872-2019
   PubMed Web of Science ®Google Scholar
• Vervloet M, Weesie Y, Kocks JWH, Dijk L, Korevaar van J. Asthma Medication in Dutch Primary Care. Asthma Medication Use and Its Relation with Asthma Outcomes. Utrecht: Nivel; 2020.
   Google Scholar
• Bloom CI, Cabrera C, Arnetorp S, et al. Asthma-related health outcomes associated with short-acting β2-agonist inhaler use: an observational UK Study as part of the SABINA global program. Adv Ther. 2020;37(10):4190–4208. doi:10.1007/s12325-020-01444-5
   PubMed Web of Science ®Google Scholar
• Murphy KR, Meltzer EO, Blaiss MS, Nathan RA, Stoloff SW, Doherty DE. Asthma management and control in the United States: results of the 2009 asthma insight and management survey. Allergy Asthma Proc. 2012;33(1):54–64. doi:10.2500/aap.2011.32.3518
   PubMed Web of Science ®Google Scholar
• Bosnic-Anticevich S, Kritikos V, Carter V, et al. Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed-dose combination.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2019.
   Google Scholar
• Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011;128(6):1185–1191. doi:10.1016/j.jaci.2011.09.011
   PubMed Web of Science ®Google Scholar
• Poulos LM, Cooper SJ, Ampon R, Reddel HK, Marks GB; Australian Institute of Health and Welfare. Mortality from Asthma and COPD in Australia. Cat. No. ACM 30. Canberra: AIHW; 2014.
   Google Scholar
• Ponieman D, Wisnivesky JP, Leventhal H, Musumeci-Szabó TJ, Halm EA. Impact of positive and negative beliefs about inhaled corticosteroids on adherence in inner-city asthmatic patients. Ann Allergy Asthma Immunol. 2009;103(1):38–42. doi:10.1016/S1081-1206(10)60141-X
   PubMed Web of Science ®Google Scholar
• McKibben S, Bush A, Thomas M, Griffiths C. “Tossing a coin:” defining the excessive use of short-acting beta 2-agonists in asthma—the views of general practitioners and asthma experts in primary and secondary care. NPJ Prim Care Respir Med. 2018;28(1):26. doi:10.1038/s41533-018-0096-4
   Web of Science ®Google Scholar
• Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med. 2004;140(10):802. doi:10.7326/0003-4819-140-10-200405180-00010
   PubMed Web of Science ®Google Scholar
• Blakeston S, Harper G, Mancebo JZ. Identifying the drivers of patients’ reliance on short-acting β2-agonists in asthma. J Asthma. 2020;1–8. doi:10.1080/02770903.2020.1761382
   Web of Science ®Google Scholar